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International day against drug 
abuse and illicit trafficking 
‘Global action for healthy communities without drugs’, 
was the theme of this year’s International day against 
drug abuse and illicit trafficking (26 June) (1). It is also 
the focus of the international campaign led by the  
United Nations Office on Drugs and Crime (UNODC) 
to raise awareness on the major challenge that illicit 
drugs represent to society as a whole, and especially  
to the young. With this slogan, this year’s initiative aims  
to promote approaches that empower and support 
community-based strategies.
The EMCDDA celebrated this international day with  
an awareness-raising event on 24 June for the Lisbon 
diplomatic community and its partners from the 
Portuguese authorities. Speaking at the event, EMCDDA 
Director Wolfgang Götz stressed the importance of this 
year’s theme, stating that successful approaches to 
preventing and treating drug use and ensuring safe and 
healthy environments often involved a wide range of 
partners, including families, schools and communities. 
Mr Götz underlined that drug use in Europe remained  
a major threat to public health, being responsible for 
between 7 000 and 8 000 fatal overdoses every  
year in the EU (2). Preventing drug use and offering 
effective treatment to those with substance use problems 
were central pillars of Europe’s response to drugs, he 
added. Today, at least 1 million people in the EU 
receive some form of treatment for drug problems per 
year. On 23 June, the EMCDDA launched a new series 
of Drug policy profiles (see page 7), while UNODC 
released its 2011 World drug report. 
(1) www.unodc.org/drugs
(2) www.emcdda.europa.eu/news/2011/m-1
The European Commission published on 11 July  
the results of its fourth survey exploring Youth attitudes 
on drugs (1). This ‘Flash Eurobarometer’ is based on 
telephone interviews conducted in May 2011 with  
over 12 000 randomly selected young people (aged 
15–24) in all 27 EU Member States. It builds on three 
earlier Eurobarometer surveys carried out in 2002, 
2004 and 2008. 
Among the issues covered by the survey are: 
perceptions on the health risks of drug use; attitudes  
to banning or regulating substances; views on the 
availability of drugs; and opinions on the effectiveness 
of policies. For the first time, questions were included 
on new psychoactive substances (‘legal highs’). 
On average, around 5 % of the young respondents 
said that they had used ‘legal highs’, with Ireland  
(16 %), Latvia (9 %), Poland (9 %) and the UK (8 %) 
reporting higher rates and Italy, Malta and Finland  
(all around 1 %) reporting lower rates. These 
substances were mainly obtained through friends  
(54 %), at parties or in clubs (37 %), in specialised 
shops (33 %) or over the Internet (7 %).
The survey shows that young people’s attitudes to  
drugs remain substance-specific. Occasional drug use 
(used once or twice) was perceived as a ‘high risk’  
to health by 23 % of respondents regarding cannabis, 
compared with 59 % for ecstasy and 66 % for 
cocaine. Regular drug use was rated as a ‘high risk’  
by 67 % of respondents for cannabis and by over  
90 % for cocaine or ecstasy. Those who had already 
used cannabis had a lower perception of its health 
risks than never-users. 
Around a quarter of those surveyed (26 %) reported 
having used cannabis at least once in their lifetime  
and perceived it to be the easiest illicit drug to obtain. 
Over half (57 %) of the respondents believed that 
obtaining cannabis within 24 hours was ‘fairly easy’  
or ‘very easy’, against 22 % for ecstasy or cocaine  
(96 % for alcohol, 95 % for tobacco). 
The survey revealed that 64 % of young people would 
use the Internet as their main source of information  
on drugs, while 37 % would talk to friends and 28 %  
to family. 
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Young people’s attitudes to drugs remain substance-specific.
Continued on page 8
Newsletter of the European Monitoring Centre for Drugs and Drug Addiction
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Drug situation
Indicators of drug supply in Europe: call for input 
Mapping GPS questionnaires 
The EMCDDA has launched on its website a call 
for contributions to the development of potential 
indicators in the areas of drug markets, drug-
related crime and drug supply reduction.  
Experts’ suggestions, comments and ideas are 
invited for all three areas, in preparation for 
working group sessions on these topics to be 
held in Lisbon in October 2011.
The need to scale up the monitoring of illicit drug 
supply in Europe is an important component of 
the current EU drugs action plan and EMCDDA 
work programme 2010–12. In October 2010, 
the first European conference on drug supply 
indicators initiated work on the conceptualisation 
of technically sound and sustainable indicators  
in this area of key importance for European  
drug policy (1). 
According to the strategy adopted at the 
conference, the overall conceptual framework  
General population surveys (GPS) represent one 
of the most fundamental, and widely used,  
data-collection tools on drug use in the countries 
of the European Union and Norway today. 
The EMCDDA’s European Model Questionnaire 
(EMQ) was launched in 2002 to provide  
a template for the construction of comparable 
surveys (1). While many countries now follow 
the EMQ, others with long-standing survey series 
may not. The latter maintain their national 
comparability over time by employing the same 
questions year on year (which may differ from 
the EMQ questions). 
To continue its work to standardise data-
collection methods on drug use in the general 
population, the EMCDDA has recently mapped 
GPS questionnaires in 24 European countries. 
The project, which kicked off in October 2010, 
compares all of the key questions on substance 
use and other issues (e.g. attitudes, perceptions) 
employed in recent national surveys of  
the general population (2).
The wording of each key question is now stored 
in a common and user-friendly database in the 
form of a ‘questionnaire map’. This map, which 
will be updated periodically, provides the 
to monitor illicit drug supply will integrate the  
three above-mentioned areas. This year, the 
corresponding working groups, supported by  
the EMCDDA, will produce a roadmap 
comprising short, medium and long-term 
monitoring objectives for the three domains. 
Contributions to the development  
of these indicators should be sent to  
paulete.duque@emcdda.europa.eu  
by 31 August.
Chloé Carpentier
EMCDDA and its partners with a sound basis 
when conducting common analyses and  
comparing GPS data in different European 
countries and when designing surveys. 
The project represents a further step towards 
greater comparability of European surveys and a 
more complete harmonisation of data.
Alexandra Ionescu and  
Deborah Olszewski 
(1) Organised by the European Commission and 
the EMCDDA with the active involvement of Europol  
www.emcdda.europa.eu/publications/drugnet/
online/2011/73/article3
For background information and conference conclusions, see: 
www.emcdda.europa.eu/events/supply-indicators and
www.emcdda.europa.eu/publications/supply-indicator-
conference-2010/conclusions
Research
EMCDDA cooperates in 
ongoing studies
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Drug-related research is crucial to 
understanding Europe’s drug problems.  
In recent years, the subject has received 
increased attention, with several European 
Commission (EC)-funded projects launched. 
The EMCDDA is currently cooperating with 
three of these projects. 
Addictions and lifestyles
Alice-RAP (Addictions and Lifestyles In 
Contemporary Europe — Reframing 
Addictions Project) is a large-scale project 
under the EC’s 7th Framework programme 
(FP7: socio-economic science and 
humanities). Over 100 researchers and  
43 research organisations are involved in this 
project, which runs for the period 2011–16, 
with a budget of EUR 10 million. The project 
covers addictive substances as well as 
behavioural addictions, such as gambling.
https://sites.google.com/site/alicerapproject 
Methodological tools 
‘New methodological tools for policy and 
programme evaluation’ will run from March 
2011 to February 2012, with a budget of  
EUR 750 000. Partially funded by the 
Commission’s ‘Drug prevention and information 
programme’, this study aims to develop 
indicators for monitoring and evaluating drug-
related interventions and policies.
www.drugpolicyevaluation.eu
EU illicit drugs market 
‘Further analysis of the EU illicit drugs market 
and responses to it — responding to future 
challenges’ is a follow-up of the 2008  
EC-commissioned ‘Report on the global  
illicit drugs market 1998–2007’. It aims to 
develop a more in-depth analysis of various 
features of the EU illicit drugs market.
http://ec.europa.eu/justice/newsroom/
contracts/318374_en.htm
Margareta Nilson and Maria Moreira 
Photo: istockphoto.com
Mapping GPS questionnaires: 
a further step towards greater 
comparability 
(1) www.emcdda.europa.eu/html.cfm/index58052EN.html
(2) The questionnaire map was presented to the EMCDDA’s 
annual GPS expert meeting in June 2011.
3Responses
Prevention science award for EMCDDA staff member
Minimum quality standards in drug demand reduction
Best practice: identifying 
key topics at national level
The 2011 International Collaborative  
Prevention Research Award went to EMCDDA 
staff member Dr Gregor Burkhart for his 
‘outstanding contribution to advancing the  
field of prevention science’ (1). 
An initiative of the Society for Prevention 
Research (SPR), the accolade is bestowed  
on an individual, or team of individuals, for 
contributions to prevention science in the area  
of international collaboration. 
Dr Burkhart, an active SPR member for several 
years, accepted the tribute at the society’s 
annual award ceremony in Washington on  
2 June. He was singled out for his efforts in 
fostering the application of prevention science  
in Europe and connecting US and EU prevention 
researchers through scientific panels and  
cross-national research collaboration. 
Such collaboration resulted in the  
establishment of the European Society for 
Prevention Research in 2010. A second meeting  
of this new body will be hosted by the 
EMCDDA from 9–10 December in Lisbon (2).
In Europe, Dr Burkhart has documented prevention 
programming and highlighted outcomes of 
prevention research trials. Along with his 
colleagues at the EMCDDA, he has also been 
instrumental in establishing a Best practice portal 
which covers prevention (3). Furthermore, he has 
been actively involved in the coordination of the 
EU-Drug Abuse Prevention (EU-Dap) trial to assess 
the effectiveness of a school-based prevention 
curriculum, ‘Unplugged’ (now being disseminated 
across Europe).
Dr Burkhart holds a vision of what effective 
prevention can do for young people, based on 
general frameworks that are not country-centric. 
This vision, along with his commitment to 
prevention, is evident in his work, earning for him 
the respect of his colleagues.
Prof. Zili Sloboda, SPR founder
Improving the quality and effectiveness  
of prevention, treatment, harm reduction, 
rehabilitation and social reintegration is  
a priority set by the current EU drugs strategy 
(2005–12). To achieve this important goal,  
the EU drugs action plan 2009–12 tasks the 
European Commission — in cooperation  
with the EMCDDA — to develop a European 
consensus on minimum quality standards  
and benchmarks in the field of drug  
demand reduction. 
Over 120 stakeholders — including  
policymakers, practitioners, NGOs  
and researchers — met in Brussels from  
15–17 June, for a Commission-organised 
conference on this issue (1). Held in 
association with the Hungarian Presidency  
of the EU, the event analysed the initial 
findings of an EC study which proposes  
a range of such minimum standards.  
Among the themes addressed at the 
conference was the translation of standards 
into practice and overcoming barriers  
Highlighting interventions that work in  
the field is a key element in promoting  
best practice. Likewise, analysing the 
information needed by national drug 
professionals to assist drug users is an essential 
part of our work. 
In this light, the EMCDDA has created a system 
to exchange information and communicate  
on the most relevant issues for drug 
professionals, based on the experiences  
of their day-to-day work.
A comprehensive strategy to establish  
a best practice communication platform was 
presented at a workshop organised at the 
EMCDDA on 12 April. Attended by some  
20 national focal points, the meeting was  
a first step towards developing a best 
practice network. 
After collecting and analysing issues of 
relevance to professionals around Europe, 
the participants drew up a list of new topics 
to be included in the Best practice portal. 
The first topic to be highlighted will be 
fentanyl dependence, as highlighted by 
Estonia. An overview will be presented  
this summer in the ‘Treatment’ module for 
opioid users (1). 
Marica Ferri  
(bestpractice@emcdda.europa.eu) 
to implementation. Four different national 
approaches were examined in this light 
(Czech Republic, the Netherlands, the  
UK and Switzerland). 
Stakeholder feedback will be incorporated  
into the final study report due in December 
2011. The European Commission will draw  
on the study’s recommendations to propose  
an EU consensus on minimum quality standards 
in drug demand reduction, planned for 2013. 
Caroline Hager, DG Justice, European 
Commission
(1) www.preventionresearch.org/about-spr/awards/2011-
awards-presentation 
(2) www.emcdda.europa.eu/publications/drugnet/
online/2011/73/article7
(3) www.emcdda.europa.eu/themes/best-practice/
evidence/universal-prevention
(1) For more, see ‘Building an EU consensus for minimum 
quality standards in the prevention, treatment and 
harm reduction of drugs’: http://ec.europa.eu/justice/
newsroom/anti-drugs/events/110615_en.htm
(1) www.emcdda.europa.eu/best-practice/treatment/
opioid-users
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Best practice portal: 
fentanyl dependence  
under the spotlight
emcdda.europa.eu/best-practice
Stakeholder feedback will be 
incorporated into the final study 
report due in December 2011
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Current approaches 
to drugs tend to be 
determined by 
medical and criminal 
perspectives, with 
the concepts of 
addiction, on the one hand, and drug control 
on the other, being central notions in drugs 
discourse. Drugs and culture: knowledge, 
consumption and policy presents alternative 
voices and understandings of drug issues, 
highlighting the socio-cultural features of 
consumption and regulation in modern 
societies. Among others, this collection of 
essays explores how the use of specific 
psychoactive substances becomes 
associated with particular social groups  
and what factors determine the political  
and policy responses to drug use.  
The book has its roots in an international 
conference held in Paris in 2008, organised 
by the French monitoring centre for drugs  
and drug addiction (OFDT) and the  
Public health Chair at Sciences Po  
(www.droguesetcultures2008.com).
EMCDDA authors contribute to two chapters 
on: ‘Drug use in Europe: specific national 
characteristics or shared models?’ and 
‘Knowledge and policies to reduce  
drug supply in France’. 
Editors: Geoffrey Hunt, Maitena Milhet, 
Henri Bergeron
Publisher: Ashgate Publishing
Language: English
Date: May 2011
ISBN: 978-1-4094-0543-6 (hardback)
(Also available as an e-book  
978-1-4094-0544-3)
www.ashgate.com/default.aspx?page=2843
Price: GBP 65 (website price GBP 58.50)
Ordering information: www.ashgate.com 
The EMCDDA is responsible for the selection 
of materials for the Bookshelf and for the text 
presented. However, responsibility for the content 
of these materials and the opinions expressed 
therein lies with the authors themselves.
Bookshelf
Drugs and culture
Feature
Forum on new drugs — reflections and conclusions 
The First international multidisciplinary  
forum on new drugs, organised by the 
EMCDDA in Lisbon from 11–12 May (1), 
brought together experts from a wide  
range of disciplines to discuss what might  
be described as a paradigm shift in our 
understanding of ‘the drug problem’. 
Delegates came from all over the world  
to discuss how a broad range of new  
drugs — e.g. mephedrone, BZP and 
synthetic cannabinoids — had begun to  
be used in their countries and how policies 
had been developed in response. 
While there were differences in the where 
and when of how particular drugs had 
appeared in individual countries, there  
was a strong impression of commonality.  
This was a global phenomenon, driven by 
the Internet, with striking similarities across the 
world in the names and packaging 
associated with these substances. 
Another overriding impression from 
participants’ accounts was one of dynamism: 
as one new drug and its use subsided, 
another unrecognised substance emerged  
to replace it. While legal controls appeared 
to work in terms of suppressing production 
and use, by the time one of these drugs  
was on the legal schedule, clandestine 
chemists and producers had already moved 
on to producing alternative uncontrolled 
substances. Producers therefore appeared  
to be one step ahead of both forensic 
scientists and the law. One danger of this 
potentially endless ‘cat-and-mouse’ game 
was that producers, and therefore users, 
were pushed further and further into the 
realm of untried and untested drugs. 
Potential solutions discussed at the  
forum included: public health warnings in 
response to suspected dangers; working with 
the media to publicise harms; introducing 
general legislation that covered whole groups of 
substances; and using laws relating to medicines 
or consumer protection to put the legal onus of 
product safety on the producer.
A further key issue highlighted at the event  
was the need to move from a purely reactive,  
to a more proactive, response. With the benefit 
of hindsight, it was possible to see how drugs, 
such as BZP, were likely to prove popular with 
both producers and users. Perhaps with better 
foresight, experts could identify substances likely 
to become the new drugs of the future. 
The need to recognise potential problems more 
quickly was also underlined. Methods to identify 
new waves of use as they broke, rather than 
after the event, could include: monitoring Internet 
chatrooms; testing wastewater; and using 
information from hospital emergency 
departments and poison centres. 
A resounding impression was that the  
world was changing fast and that drug  
use was changing with it. This threw up  
major challenges for those working in the  
drugs field, be they scientists, researchers or 
policymakers. In this context, many speakers 
and participants emphasised the importance  
of the timely sharing of knowledge and 
information at global level. The forum was  
a first step in this direction.
Charlie Lloyd, University of York, and  
Ana Gallegos, EMCDDA
New psychoactive substances: 
a paradigm shift in our 
understanding of  
‘the drug problem’
(1) See news releases 1/2011 and 2/2011 at 
www.emcdda.europa.eu/news/home
See also Drugnet Europe No 74 and concluding remarks at:
www.emcdda.europa.eu/events/2011/new-drugs-forum
A global phenomenon, driven 
by the Internet
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5Drug prices  
Monitoring wholesale drug prices in Europe
The EMCDDA has been collecting and 
analysing routine data on Europe’s drug 
markets since the mid-1990s, focusing on 
seizures, drug purity/potency and on retail 
drug prices. In 2009, it also embarked on a 
project to assess the feasibility of monitoring 
wholesale drug prices and purity-adjusted 
prices in Europe (1). Building on this study, the 
EMCDDA launched a ‘Pilot study of 
wholesale drug prices in Europe’ in 2010, 
providing an overview of information 
available in EU countries (2). 
Whereas retail drug prices indicate what users 
pay for a given drug, wholesale prices show 
what drug dealers pay to major distributors in 
the market where the drug is consumed.  
By comparing the two, estimates can be made 
of the maximum profit margins that drug 
traffickers may obtain in the retail market.
The pilot study reveals that, in 2008, the 
wholesale price for consignments of one 
kilogram of cocaine can be estimated at 
between EUR 31 000 and EUR 58 000, 
with most countries reporting figures around 
EUR 35 000. When reported, the average 
purity level of such consignments was close 
to 70 %. 
In 2008, retail cocaine prices reported were 
25 % to 83 % higher than wholesale prices. 
Purity levels decreased when moving from the 
wholesale to retail market, where they were 
reported to be on average between 13 % and 
60 %, depending on the country. Additional 
data are, however, required to estimate precisely 
the purity-adjusted price differences between the 
wholesale and retail level.
During the implementation of the pilot study,  
the utility of improving current data-collection 
systems was analysed and the required 
investments assessed. As a result, 10 countries 
have revised, or plan to revise, their current 
data-collection practices. 
Cláudia Costa Storti 
Enlargement Research and innovation
Croatia launches first GPS on drugs Stakeholders have their say on EU funding 
Croatia is one of eight candidate and potential candidate countries  
to the EU currently receiving EMCDDA technical assistance, under  
the European Commission’s Instrument for Pre-Accession (IPA) 
programme. In May 2011, co-funded by the EMCDDA’s IPA 3 
project (see page 6), Croatia launched its first general population 
survey (GPS) on drugs. The survey of 4 000 individuals will provide 
insight into the prevalence and patterns of psychoactive substance use 
in Croatia, as well as the attitudes to drugs of different population 
groups. The results, to be available at the end of this year, will help 
tailor interventions to drug users and those affected by drug use. 
Another important outcome of the ongoing assistance is the integration 
of the best practice concept into Croatian procedures. The Office  
for Combating Drug Abuse (hosting the NFP) set up a national 
database earlier this year which: monitors the quality of projects  
in the area of drug demand reduction; encourages evaluation;  
and promotes best practice. The IPA 3 project also supported  
the organisation of four regional workshops on best practice in  
May 2011, where over 180 experts were acquainted with  
new developments in the field and invited to participate  
in follow-up activities.
Finally, following an IPA 3-supported national conference on  
new psychoactive substances in Zagreb in April 2011, the Croatian 
early-warning network has been widened. Newly established expert 
focus groups will allow for the more rapid detection of new drugs  
and emerging trends and more timely interventions to protect the 
health of users.
Lidija Vugrinec (Head of the Croatian national focal point)  
and Dijana Jerković (expert at the NFP) 
The results of a public consultation on future EU funding for research  
and innovation were discussed at a major conference organised by 
the European Commission in Brussels on 10 June (1)(2). The consultation, 
which closed on 20 May, was based on a Commission Green Paper 
published on 9 February. This proposed ways to: make EU funding 
more attractive and accessible; increase the scientific and economic 
impact of funded projects; and ensure better value for money. 
Over 800 stakeholders from research, industry, academia, science 
and politics took part in the consultation. The EMCDDA Scientific 
Committee featured among these, contributing with a position paper 
on specific drug-related research funding challenges for the future, 
adopted at its May meeting (3). 
Participants at the conference concluded that funding should be made 
available for ‘curiosity-driven’ as well as ‘agenda-driven’ research 
topics and should be less prescriptive and accessible to small groups 
as well as large consortia. They also agreed that funding procedures 
should be simplified and that research and innovation be addressed 
under one framework that would contribute to tackling societal 
challenges. Changes sparked by the consultation and conference will 
be introduced under the next EU research and innovation budget (post-
2013). This will cover: the 7th Framework programme for research 
(FP 7); the Competitiveness and innovation programme; and the 
European Institute of Innovation and Technology.
Maria Moreira 
(1) www.emcdda.europa.eu/publications/drugnet/
online/2009/67/article7
(2) To be available on the EMCDDA website in September. 
(1) http://ec.europa.eu/research/csfri/index_en.cfm 
(2) ‘Conference on the common strategic framework for EU research and innovation 
funding’: http://ec.europa.eu/research/csfri/index_en.cfm?pg=events
(3) www.emcdda.europa.eu/themes/research
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Spotlight
New formula put  
to the test
Reitox
IPA 3 project progresses in Albania
Cooperation with Malta: new momentum 
A new Country overview, a national drug  
report and first-time participation in the 
European School Survey Project on Alcohol  
and Other Drugs (ESPAD), will be among the 
outcomes of the EMCDDA’s technical  
assistance project in Albania under the 
European Commission’s Instrument for  
Pre-Accession (IPA) programme.
Albania is one of eight candidate and  
potential candidate countries to the EU currently 
receiving EMCDDA assistance, under a  
EUR 900 000 project which kicked off in  
April 2010 (IPA 3). The project, which will run 
until November 2011, is designed to help the 
eight partners establish national drug information 
systems in line with EU standards (1). 
Important partners in the project are ‘Reitox 
coaches’: representatives from EU national focal 
points (NFP) assigned to assist the partners in 
running national activities according to EU 
norms. The Reitox coach for Albania made  
two visits to the country in 2010, in partnership 
with the Albanian representative from the 
National Institute of Public Health (the project’s 
‘national correspondent’). 
The aim of the first visit (June 2010) was to  
draw up a plan of activities for the period 
2010–11, with input from a variety of Albanian 
stakeholders. This led to the completion of the 
Country overview and an information map, to 
be published on the EMCDDA website  
this autumn (2). The EMCDDA national 
reporting guidelines were discussed with an 
Albanian working group of experts during  
the second visit (December 2010). This group 
will assist the national correspondent in writing 
the first integrated Albanian national report  
on the drug situation, due for completion  
in October.
Other IPA 3-project-related national activities 
include the translation into Albanian of  
the five EMCDDA epidemiological key  
indicator protocols; a developmental project  
in the area of the treatment demand indicator; 
and a national training event in the area of 
problem drug use.
Frédéric Denecker, Ernestas Jasaitis  
(Reitox coach) and Eduard Kakarriqi 
(national correspondent) 
Cooperation between the EMCDDA and Malta gained momentum this spring with the signature  
of a grant agreement on 6 April between the agency and the Maltese national focal point (NFP). 
The event took place on the occasion of the official visit of EMCDDA Director Wolfgang Götz to 
Malta, at the invitation of Minister of Education, Employment and the Family, Dolores Cristina.  
The agreement guarantees co-financing by the EMCDDA of the national focal point for 2011 and  
paves the way for its future development. 
Minister Cristina underlined the commitment of her country to consolidate the NFP and the  
national drug information network. Mr Götz thanked the Minister for her support and stressed the 
added value of a strong Maltese focal point in the European drug information system. He also 
acknowledged the valuable contribution of EMCDDA Management Board member Professor 
Richard Muscat to re-establishing the NFP (1).
The agreement was signed by the Ministry’s Director of Corporate Services, André Vassallo Grant, 
and Alexis Goosdeel, Head of the EMCDDA’s Reitox and international cooperation unit. 
The EMCDDA holds grant agreements with the NFPs in all 27 EU Member States. Under these 
agreements, the agency can finance up to half of the Reitox actions, with the Member State 
financing the same amount. 
Alexis Goosdeel
(1) The eight partners are: Albania, Bosnia-Herzegovina, 
Croatia, the Former Yugoslav Republic of Macedonia, 
Kosovo (under UNSCR 1244/99), Montenegro, Serbia 
and Turkey. See Drugnet Europe No 74.
(2) www.emcdda.europa.eu/publications/country-
overviews
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A new formula for Heads of national focal 
point (NFP) meetings was put to the test from  
18–20 May and scored well with 
participants in a final evaluation. For many 
years, these plenary meetings have acted  
as an all-purpose forum for content-related 
discussions and updates as well as decision-
making on contractual arrangements 
between the EMCDDA and NFPs.  
Pressure on the agenda increased when  
the network doubled in size between  
2004 and 2010, and when the annual 
meetings were cut from three to two, for 
budgetary reasons, in 2005.
The new structure was conceived to ease 
this pressure by promoting a more 
participative approach through smaller 
thematic workshops. Each workshop is set 
clear objectives ahead of the meeting and 
the conclusions are duly documented to 
facilitate follow-up and further action. 
The new approach allows for formal 
decision-making procedures to be dealt with 
separately from content-oriented debates. 
This separation is particularly important in 
the perspective of cooperation with 
candidate and potential candidate countries 
and, in the mid-term, with neighbouring 
countries, which do not have a contractual 
relationship with the EMCDDA. 
While the participants identified the need  
for some fine-tuning of the new model, they 
welcomed it unanimously. It was felt that  
a focus on greater participation and sharing 
of experience would help the EMCDDA and 
the network welcome new countries, adapt 
more quickly to changing circumstances, be 
more efficient and continually improve and 
maintain the relevance of its outputs.
Alexis Goosdeel, Alan Lodwick,  
Tim Pfeiffer-Gerschel 
(1) The Maltese national focal point was not operational during the period 2009–10.
7Launched in September 1996, Drugnet Europe is one of the EMCDDA’s 
central communication tools, regularly conveying the latest news from 
the agency, the Reitox network and the EMCDDA’s institutional and 
international partners. Over the years, the newsletter has undergone a 
number of changes in design, content, format, style and frequency.  
In order to engage with Drugnet Europe readers and assess how the 
product is received, a survey has been launched on the EMCDDA 
website. We invite readers to respond to a short questionnaire 
(deadline: 15 November). Your feedback will help us ensure cost-
effective communication and a relevant coverage of issues.
Survey accessible at www.emcdda.europa.eu/publications/drugnet/survey
Drug policy profiles — Portugal
Ahead of International day against drug abuse and illicit trafficking, the 
EMCDDA launched, on 23 June, a new series of Drug policy profiles. 
This new series aims to describe some of the main characteristics of 
national drug policies in Europe and elsewhere in the world. The first 
edition describes the national drug policy of Portugal, a policy that has 
attracted significant attention recently in the media and in policy debates. 
The profiles do not attempt to assess national policies, but instead outline 
their development and main features. The objective is to help readers — 
from researchers to policymakers — gain a better understanding of the way in which countries 
control drugs and respond to drug-related social and health problems. 
Available in English at www.emcdda.europa.eu/publications/drug-policy-profiles/portugal
Preventing infections among people who inject drugs 
Guidance on infection prevention and control among people who inject drugs will be the 
focus of a joint ECDC–EMCDDA publication to be launched on 12 October in Lisbon.  
The publication aims to inform and support public health decision-makers, at national and 
regional level, who work in areas such as infectious diseases, addiction, mental health and 
drug control. Designed as a resource for shaping informed public health responses to 
injecting drug use in the EU Member States and beyond, it brings together expert knowledge 
on practices to prevent infectious diseases in this highly vulnerable group. The guidance is 
based on the latest available evidence.
Coming soon in English at www.emcdda.europa.eu/publications/joint-publications
Amphetamine: a European Union perspective  
in the global context
Amphetamine: a European Union perspective in the global context is the 
title of the upcoming third edition in the EMCDDA–Europol series of joint 
publications dedicated to prevalent illicit drugs. The new study, to be 
launched in the autumn, focuses on amphetamine production and 
markets in Europe, set in a global context. Previous editions in the series 
covered methamphetamine and cocaine, whilst upcoming volumes will 
focus on ecstasy-type substances, heroin and cannabis. The series is one 
of several collaborative activities agreed by the two agencies for the 
period 2009–12 (www.emcdda.europa.eu/about/partners/europol).
Coming soon in English at www.emcdda.europa.eu/publications/joint-publications
For more on this series, see www.emcdda.europa.eu/publications/illicit-drugs
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First international forum on 
new drugs
Leading European and international experts in the field 
of new psychoactive substances met in Lisbon from  
11–12 May for the First international multidisciplinary 
forum on new drugs (1). Ahead of the event, EMCDDA 
Director Wolfgang Götz referred to the dynamic nature 
of the new drugs phenomenon and the timeliness of an 
event of this kind. ‘The purpose of the forum is to arrive 
at a comprehensive vision for the future regarding how 
these substances will impact on drug use, responses 
and policies’, he said.
The aim of the forum was to take stock of the current 
state of the art in this area and identify common anchor 
points to inform future actions. The programme focused 
on early-warning systems, risk assessments and controls, 
as well as options for prevention and treatment. In 
discussions, the experts traced how this phenomenon 
has developed over the last 10 years and compared, 
through case studies, differing national experiences.  
The 100-strong forum included: forensic scientists; 
epidemiologists; clinicians; law-enforcement experts 
concerned with new drugs; as well as technical staff 
from EU and international institutions.
The forum was organised in conjunction with the 
11th Annual meeting of the EMCDDA–Reitox early-warning 
system (EWS) network. The EWS provides EU Member 
States with an information exchange mechanism for 
reporting on the emergence of new psychoactive 
substances. It is a key element in the European fast-track 
system for assessing and responding to new drugs.
Roumen Sedefov and Ana Gallegos 
New psychoactive substances are becoming widely 
available at an ‘unprecedented pace’. This is 
according to the EMCDDA–Europol 2010 report on 
new drugs entering the European market (1), released 
on 11 May at the Annual meeting of the EMCDDA–
Reitox early-warning system (EWS) network (see 
opposite). Once again, in 2010, a record number of 
new drugs were officially reported to the EMCDDA 
and Europol via the EU early-warning system (EWS) 
on new psychoactive substances. 
According to the report, 41 new psychoactive 
substances were officially notified for the first time to 
the two agencies in 2010. This represents the largest 
number of substances ever reported in a single year, 
considerably up on 2009 (24 substances) and 
2008 (13 substances).
The full list of substances notified, annexed to the 
report, shows a ‘rather diverse’ group, including: 
synthetic cannabinoids, synthetic cathinones, synthetic 
derivatives of well-established drugs as well as one 
plant-based substance (arecoline) (2).
Under the so-called ‘Spice’ phenomenon (3),  
11 new synthetic cannabinoids were picked up in 
2010, bringing the total number of these substances 
monitored by the EWS up to 27. Responding to  
health concerns, at least 16 European countries have 
now taken legal action to ban or otherwise control 
‘Spice’ products and related compounds.
The report gives an account of the risk assessment of 
the synthetic cathinone derivative, mephedrone, which 
led to the decision for Europe-wide controls on the 
drug in December 2010 (4). A further 15 synthetic 
cathinone derivatives were detected during the year. 
Also documented is the first-time appearance of 
derivatives of two established drugs: ketamine and 
PCP (phencyclidine). 
With a large number of new unregulated synthetic 
compounds marketed on the Internet as ‘legal highs’, 
the report describes the EMCDDA’s activities in 
monitoring the online shops selling these substances. 
Commenting on this year’s findings, EMCDDA 
Director Wolfgang Götz said: ‘Given the speed at 
which new developments occur in this area, it is 
important to anticipate future challenges. 
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New psychoactive substances are becoming widely available at 
an ‘unprecedented pace’.
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(1) www.emcdda.europa.eu/events/2011/new-drugs-forum 
Resources
Events and materials on 
the drugs issue
Guia de recursos 
da saúde e 
dependências
This guide to resources and 
responses in the area of drug 
addiction in Portugal was 
published this spring and is 
now available online in 
Portuguese. The publication presents a vast and 
qualified network of institutions operating throughout 
the country as well as the evolution of the 
Portuguese drug policy. Also included is a section 
on international bodies working in the field, where 
the EMCDDA and its Reitox network are presented. 
For more, see www.dependencias.pt
Harm reduction conference
The European harm reduction network (EuroHRN), 
established in 2010, will hold its 1st European 
conference on harm reduction from 6–7 October in 
Marseilles. The meeting will gather the network’s 
members and concerned stakeholders with the aim 
of: sharing an assessment on the harm reduction 
situation within Europe; improving the EuroHRN  
sub-regional networks (southern, northern and 
central-eastern European networks); and developing 
the European drug users’ network.
For more, see www.eurohrn.eu/
Global Addiction 2011
Global Addiction 2011 is an international 
conference to be held in Lisbon from 5–7 
December. The event has evolved from the former 
European Association of Addiction Therapy 
conferences, the last of which was held in 2009. 
Organised by the Global Addiction Network, the 
2011 event will bring speakers from around the 
globe to present on a wide spectrum of topic areas 
pertinent to addiction and the treatment of addictive 
disorders. The EMCDDA will participate in a 
session on ‘Innovation and quality’.
For more, see www.globaladdiction.org 
Organisations wishing to publicise their newsletters, 
magazines, websites, CD-ROMs or any other 
resources are invited to contact  
Kathryn.Robertson@emcdda.europa.eu
Products and services
Drugnet Europe survey 
OFFICIAL PUBLISHER: European Monitoring Centre for Drugs and Drug Addiction • PROPRIETOR: EMCDDA • DIRECTOR: Wolfgang Götz • EDITOR: Kathy Robertson • 
Printed in Belgium • ISSN: 0873–5379 • CATALOGUE NUMBER: TD-AA-11-003-EN-C • Printed on chlorine-free paper • © European Monitoring Centre for Drugs and Drug Addiction 
Calendar 2011
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31
Drugnet Europe is a newsletter published by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Lisbon. 
Any item may be reproduced provided the source is acknowledged.
For free subscriptions, please specify your requirements via e-mail: publications@emcdda.europa.eu
Cais do Sodré, 1249-289 Lisbon, Portugal 
Tel. (351) 211 21 02 00 • Fax (351) 218 13 17 11 
info@emcdda.europa.eu • www.emcdda.europa.eu • twitter.com/emcdda 
EMCDDA meetings
4–8 July:  EMCDDA and CADAP–DAMOS training 
event on national drug monitoring systems for 
a delegation of Kazakh experts, Lisbon.
7–9 September:  National Reitox Academy on building 
national drug observatories, Rome.
14–15 September:  Reitox Academy for IPA beneficiaries on new 
psychoactive substances and the EU early-
warning system, Tirana.
20–21 September:  EMCDDA expert meeting on the treatment 
demand indicator, Lisbon.
22 September:  Similarities and differences in treatment 
systems in Europe and consequences for 
treatment monitoring, Lisbon.
26–28 September:  Drug-related deaths training activity, Skopje.
29–30 September:  EMCDDA and TAIEX scientific seminar, Kiev. 
11–12 October:  EMCDDA expert meeting on drug-related 
infectious diseases, Lisbon. 
12 October:  Launch of ECDC–EMCDDA Guidance on 
infection prevention and control among 
people who inject drugs, Lisbon.
27–28 October:  EMCDDA expert meeting on the problem 
drug use indicator, Lisbon. 
15 November: EMCDDA Annual report launch, Lisbon.
External meetings
17–18 July:  International drugs and driving symposium, 
Montreal (www.ccsa.ca).
EU meetings
6–7 September:  Horizontal working party on drugs, Brussels. 
4–5 October:  Horizontal working party on drugs, Brussels. 
18–19 October:  EU/eastern Europe conference, Warsaw.
27–28 October:  Justice and Home Affairs Council, 
Luxembourg.
21–22 November:  National drug coordinators’ meeting, Poznán.
Statutory bodies
Scientific Committee elects new Chair  
and Vice-chair 
The EMCDDA Scientific Committee, meeting in Lisbon from 16–17 May, 
elected its new Chair and Vice-chair for the coming three years. Dr Marina 
Davoli (Italian) was elected to the position of Chair and Prof. Dr Gerhard 
Bühringer (German) to the position of Vice-chair (1).
At the meeting, the Committee discussed its strategy for the coming years, 
including earlier involvement in the development of the agency’s work 
programmes and in the preparatory phases of EMCDDA studies. Outgoing 
Chairman Prof. Michael Farrell (Irish) was thanked for his valuable 
contribution in steering the Committee over the last three years. Prof. Farrell, 
who will remain a Committee member, has recently been appointed Director 
of the National Drug and Alcohol Research Centre (NDARC), Australia. 
During the meeting, the members expressed their gratitude to EMCDDA staff 
member Margareta Nilson, who has been responsible for liaison with the 
Scientific Committee since 2005 and who will be leaving the agency in 
September. Both the Committee and EMCDDA staff wish her well in her 
retirement after 16 years of service. 
(1) See Fact sheet No 4/2011 at www.emcdda.europa.eu/news/2011/fs-4
But, when asked how they had been informed about drugs issues in the past 
year, the Internet came in third position (39 %), behind media campaigns 
(46 %) and school prevention programmes (41 %). However, figures show 
that the Internet has become a more significant drug-related information 
source than in 2008. 
In terms of drug control and regulation, the majority of respondents (59 %)  
still support cannabis prohibition, but this number has declined from 67 % 
since 2008. Regarding new psychoactive substances, respondents indicated 
that these should be banned only if they pose a risk to health (47 %) or be 
regulated in similar ways to alcohol or tobacco (15 %). Around one third of 
respondents (34 %) felt that these substances should be banned under any 
circumstances. 
Released on the same day was a European Commission assessment of the 
EU’s mechanism for addressing new psychoactive substances entering the 
European market (2). The EMCDDA contributed to this report. 
Maurice Galla, DG Justice, European Commission
Continued from page 1
Survey results: youth attitudes to drugs 
(1) http://ec.europa.eu/public_opinion/flash/fl_330_en.pdf
(2) http://ec.europa.eu/justice/anti-drugs/document/index_en.htm
